Cel
While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.
Dziedzina nauki
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinephysiologycytology
- medical and health sciencesclinical medicineoncologycervical cancer
- social scienceseconomics and businesseconomicshealth economics
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-PHC-2014-two-stage
System finansowania
RIA - Research and Innovation actionKoordynator
WC1E 6BT London
Zjednoczone Królestwo
Zobacz na mapie
Uczestnicy (14)
17177 Stockholm
Zobacz na mapie
116 36 Praha 1
Zobacz na mapie
5021 Bergen
Zobacz na mapie
20121 Milano
Zobacz na mapie
SO16 6YD Southampton
Zobacz na mapie
Podmiot prawny inny niż podwykonawca, stowarzyszony lub mający inne powiązania prawne z uczestnikiem. Podmiot realizuje prace na podstawie warunków umowy o grant, dostarcza towary lub świadczy usługi związane z działaniem, jednak nie podpisuje umowy o grant. Podmiot zewnętrzny przestrzega zasad i wymogów dotyczących danego uczestnika wynikających z umowy o grant, dotyczących kwalifikowalności kosztów oraz kontroli wydatków.
SO17 1BJ Southampton
Zobacz na mapie
80539 Muenchen
Zobacz na mapie
WC1E 7HT London
Zobacz na mapie
Zakończenie uczestnictwa
CB2 1TN Cambridge
Zobacz na mapie
3015 GD Rotterdam
Zobacz na mapie
6020 INNSBRUCK
Zobacz na mapie
80539 Munchen
Zobacz na mapie
Zakończenie uczestnictwa
LN1 1XW Lincoln
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
78467 Konstanz
Zobacz na mapie